ALVONasdaqBiological Products, (No Diagnostic Substances)

Alvotech (ALVO) earnings date, market-implied expected move, and options open interest by expiry

4.56

+0.02 · +0.41%

Regular session10:18 ET

Open4.62Volume541,165Mkt cap$1.4BP/E45.59EPS0.10

Day4.56 – 4.620%52-wk2.94 – 6.5345%

ALVO

Alvotech

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

News

30dMatvæla- og lyfjastofnun Bandaríkjanna (FDA) veitir viðbótarleyfi fyrir framleiðslu á hliðstæðunni við Humira í báðum framleiðslueiningum lyfjaverksmiðju Alvotech í Reykjavík
30dFDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
71dAlvotech (ALVO) Gets New ‘Buy’ Reco. Should Investors Follow?

News

Next report

Last report

—

Largest filed tie

40.00%

of ALVO revenue · Teva

customerALVO 20-F

Largest filed tie

13F top-10 QoQ

—

Top fund weight

0.00%

ALVO weight · VT

N-PORTJul 31 '26

No upcoming report date for Alvotech (ALVO).

Implied vs realized

No reported quarters.

Implied vs realized

Positioning

No open-interest data.

Positioning

Linked exposure

No implied move.

Linked exposure

Revenue flow

No filed income statement.

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 10:15 ET

Intraday

Event sensitivity

NFP ×1.36· ±3.1% vs ±2.3% · 10 releases

eventrelease day|move|up · n×base

NFPjobs report±3.1%3 of 10×1.36

CPROFcorporate profits±3.0%4 of 12×1.31

GDPgross domestic product±2.8%5 of 19×1.21

PCEpersonal income & outlays±2.8%8 of 19×1.20

PPIproducer prices±2.4%6 of 10×1.05

CPIconsumer prices±2.4%3 of 10×1.03

FOMCrate decision±2.0%7 of 24×0.88

Bar = avg |move| to ±4% · tick = ±2.3% avg day · ×base = |move| ÷ ±2.3% · min 6 releases

Earnings history

No reported quarters.

Methodology

ties · implied moves · holdersMethod